

02139.000017



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

YUTAKA TAKANO, ET AL.

Application No.: 09/496,041

Filed: February 2, 2000

For: PROCESS FOR PRODUCING
PURINE NUCLEOTIDES

)
: Examiner: Kathleen M. Kerr
)
: Group Art Unit: 1652
)
:
)
:
)
: April 24, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231

#20
RECEIVED

APR 25 2003

TECH CENTER 1600/2900

RESPONSE

Sir:

Applicants respond to the Office Action dated February 20, 2003
(unnumbered paper) in the above-identified application, as follows:

REMARKS

The February 20, 2003 Official Action (copy attached Tab A) states the Request for Continued Examination ("RCE") under Rule 114 filed February 11, 2003 was improper since it was not accompanied by a reply to the non-final Office Action of August 13, 2002. However, the RCE included a Petition to Suspend Proceedings for three months together with a check in the amount of \$130.00 to cover the petition fee under Rule 17(h).

~~It was understood this permitted Applicants three months to make the~~
~~necessary submission of a reply to the August 13, 2002 Office Action. However, the~~
~~commentary in Federal Register Vol. 65, No. 159 at 50094, Section 1.103(a) differs, and~~
~~provides that "[t]he Office will not suspend action if reply by applicant to an Office action"~~


~~is outstanding... [and] a request for suspension of action under §1-103(c) does not...
substitute for the submission (or fee) required by §1-114...~~

Accordingly, Applicants hereby Petition the Assistant Commissioner to treat the RCE as a Rule 53(b) continuation or alternatively, hereby Petition the Assistant Commissioner to accept the belated filing of a Rule 53(b) continuation. In either event, the necessary Rule 53(b) continuation papers^{1/} are enclosed.

The Assistant Commissioner is hereby authorized to charge any necessary Petition fees to Deposit Account No. 06-1205. The filing fee for the continuation application may simply be utilized from the filing fee (\$750.00) of the incomplete RCE, as well as the (\$130.00) fee for the improper Petition to suspend proceedings. Of course, any deficiencies in this regard may be charged to Deposit Account No. 06-1205 as well.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

NY_MAIN 341989v1

1/

Specifically, a true and complete copy of the 09/496,041 specification (Tab B), an Application Data Sheet (Tab C), a Preliminary Amendment (Tab D) and an Information Disclosure Statement (Tab E), a new application transmittal sheet (Tab F), and Statement Concerning Computer Readable Form with paper copy (Tab G).




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/496,041	02/02/2000	Yutaka Takano	2139.17	5621

5514 7590 02/20/2003

FITZPATRICK CELLA HARPER & SCINTO
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112



EXAMINER	
KERR, KATHLEEN M	
ART UNIT	PAPER NUMBER
1652	

DATE MAILED: 02/20/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

LSR

02134. 000017




APPLICATION NUMBER

FILING DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO./TITLE



DATE MAILED:

RECEIVED
APR 25 2003
TECH CENTER 1600/2900

NOTICE OF IMPROPER REQUEST FOR CONTINUED EXAMINATION (RCE)

The request for continued examination (RCE) under 37 CFR 1.114 filed on 2-11-03 is improper for reason(s) indicated below:

- ☐ 1. Continued examination under 37 CFR 1.114 does not apply to an application for a design patent. Applicant may wish to consider filing a continuing application under 37 CFR 1.53(b) or a CPA under 37 CFR 1.53(d).
- ☐ 2. Continued examination under 37 CFR 1.114 does not apply to an application that was filed before June 8, 1995. Applicant may wish to consider filing a continuing application under 37 CFR 1.53(b) or a CPA under 37 CFR 1.53(d).
- ☒ 3. Continued examination under 37 CFR 1.114 does not apply to an application unless prosecution in the application is closed. If the RCE was accompanied by a reply to a non-final Office action, the reply will be entered and considered under 37 CFR 1.111. If the RCE was not accompanied by a reply, the time period set forth in the last Office action continues to run from the mailing date of that action.
- ☐ 4. The request was not filed before payment of the issue fee, and no petition under 37 CFR 1.313 was granted. If this application has not yet issued as a patent, applicant may wish to consider filing either a petition under 37 CFR 1.313 to withdraw this application from issue, or a continuing application under 37 CFR 1.53(b).
- ☐ 5. The request was not filed before abandonment of the application. The application was abandoned, or proceedings terminated on _____. Applicant may wish to consider filing a petition under 37 CFR 1.137 to revive this abandoned application.
- ☐ 6. The request was not accompanied by the fee set forth in 37 CFR 1.17(e) as required by 37 CFR 1.114. Since the application is not under appeal, the time period set forth in the final Office action or notice of allowance continues to run from the mailing date of that action or notice.
- ☐ 7. The request was not accompanied by a submission as required by 37 CFR 1.114. Since the application is not under appeal, the time period set forth in the final Office action or notice of allowance continues to run from the mailing date of that action or notice.

Note: If a request for a continued prosecution application (CPA) under 37 CFR 1.53(d) has been filed in the utility or plant application (including a previously filed CPA) that was filed on or after May 29, 2000, the request for a CPA has been treated as a RCE because the CPA practice no longer applies to such application. The constructive RCE, however, is improper for reason(s) indicated above.

A copy of this notice MUST be returned with any reply.

Direct the reply and any questions about this notice to:

Aorothy Shonaz, Examining Group 1660

APPLICATION FOR PATENT

Inventors: Yutaka Takano
Masato Ikeda
Tatsuro Fujio

Citizens of: Japan

Post Office
Addresses: c/o Technical Research Laboratories,
KYOWA HAKKO KOGYO CO., LTD.
1-1, Kyowa-cho, Hofu-shi, Yamaguchi
747-8522 Japan

c/o Technical Research Laboratories,
KYOWA HAKKO KOGYO CO., LTD.
1-1, Kyowa-cho, Hofu-shi, Yamaguchi
747-8522 Japan

c/o Head Office, KYOWA HAKKO KOGYO
CO., LTD.
6-1, Ohtemachi 1-chome, Chiyoda-ku,
Tokyo 100-8185 Japan

Title: Process for Producing Purine Nucleotides

PROCESS FOR PRODUCING PURINE NUCLEOTIDES

Background of the Invention

The present invention relates to a process for producing
5 purine nucleotides which are in great demand as seasoning
agents, and to microorganisms useful in said process.

5'-Guanylic acid (hereinafter abbreviated as GMP) and
5'-inosinic acid (hereinafter abbreviated as IMP) are purine
nucleotides which exhibit a strong flavor-enhancing activity
10 and are widely used as chemical seasoning components.

Some processes are known for producing these
flavor-enhancing nucleotides: for example, a process which
comprises hydrolyzing RNA extracted from yeast cells with
ribonuclease P1 and then isolating and purifying the desired
15 5'-nucleotide [Food Technol., 18, 287 (1964)]; a process of
directly producing IMP by fermentation using a microorganism
having the ability to produce IMP [Agricultural and Biological
Chemistry, 46, 2257 (1982)]; a process which comprises
converting nucleosides such as inosine and guanosine into
20 nucleotides by chemical phosphorylation [Bulletin of the
Chemical Society of Japan, 42, 3505 (1969)]; a process which
comprises producing 5-amino-4-imidazolecarboxamide riboside
(hereinafter abbreviated as AICAR) by fermentation using a
mutant of Bacillus megaterium, and then producing a nucleotide
25 from AICAR by chemical synthesis [Biotechnol. Bioeng., 2, 329
(1967); J. Org. Chem., 32, 1825 (1967)]; and a process which
comprises culturing a mutant of Corynebacterium ammoniagenes
which produces 5'-xanthylic acid (hereinafter abbreviated as
XMP) in a medium to form and accumulate XMP, culturing
30 Escherichia coli increased in the activity of XMP aminase (also
known as GMP synthetase) obtained by self-cloning, and then
producing GMP from XMP by enzyme reaction using the cultured
E. coli cells as an enzyme source [Biosci. Biotech. Biochem.,
61, 840 (1997); Japanese Published Unexamined Patent
35 Application No. 233798/88].

To sum up, processes for producing flavor-enhancing

nucleotides so far developed can be classified into the following three groups in principle [Shoichi Takao, et al. (ed.), Oyo Biseibutsugaku (Applied Microbiology), Buneido Shuppan (1996)]:

- 5 (1) a method in which yeast RNA is degraded with a microorganism-derived enzyme or chemically (the RNA degradation method),
- (2) a method of directly producing a nucleotide by culturing a mutant of a microorganism in a medium containing sugars,
10 a nitrogen source and a phosphoric acid source (the direct fermentation method), and
- (3) a method which comprises producing an intermediate for the nucleotide synthesis by fermentation, and converting said intermediate into a nucleotide chemically or
15 enzymatically (the method which is a combination of fermentation and chemical synthesis or enzymatic conversion).

In the RNA degradation method (method (1) above), pyrimidine nucleotides are also produced in almost the same
20 amounts as flavor-enhancing purine nucleotides, and so the purification step necessarily becomes complicated. In the direct fermentation method (method (2) above), it is not easy to breed a microorganism which can extracellularly form and accumulate a considerable amount of nucleotides because of
25 low membrane permeability of nucleotides, and thus it is difficult to obtain an economically satisfactory productivity of nucleotides. Specifically, there has not been known a process for direct production of GMP so far. However, it is known that XMP can be exceptionally formed and accumulated
30 in considerable amounts [Shoichi Takao, et al. (ed.), Oyo Biseibutsugaku (Applied Microbiology), Buneido Shuppan (1996)]. At present, as an economically advantageous method for producing flavor-enhancing nucleotides, the combination method of fermentation and chemical synthesis or enzymatic
35 conversion (method (3)) is widely employed for industrial production of the nucleotides.

In this combination method, one of the points for the improvement of the entire productivity is to enhance the yield of an intermediate for the nucleotide synthesis in the fermentation step (the first stage of the process). To this end, a large number of microorganisms having high productivity of XMP, guanosine or inosine have been bred [Agricultural and Biological Chemistry, 42, 399 (1978); Agricultural and Biological Chemistry, 43, 1739 (1979); Agricultural and Biological Chemistry, 46, 2347 (1982)].

There have also been developed various methods of chemical or enzymatic conversion of an intermediate into a nucleotide (the second stage of the process). As a chemical method, site-specific phosphorylation reaction (nucleoside \rightarrow 5'-nucleotide) [Bulletin of the Chemical Society of Japan, 42, 3505 (1969)] is industrially used. However, the chemical phosphorylation reaction requires the intermediate step to purify a nucleoside as a phosphate group acceptor to the necessary extent and also requires the use of a chemical reaction vessel in addition to a fermentor used for the fermentation step. Therefore, the enzymatic methods using aminase or phosphorylase attract attention and have been studied. As for the amination, a method using XMP aminase is known [Shoichi Takao, et al. (ed.), Oyo Biseibutsugaku (Applied Microbiology), Buneido Shuppan (1996)].

As for the phosphorylation, methods using phosphotransferase, kinase and phosphatase are known. In particular, the reaction utilizing kinase or phosphatase has been studied as an efficient method. For example, there have been developed a process for producing a 5'-nucleotide by the use of an Escherichia coli strain carrying a gene encoding inosine-guanosine kinase of Escherichia coli (W091/08286), a process for producing a 5'-nucleotide by the use of a Corynebacterium ammoniagenes strain carrying a gene encoding inosine-guanosine kinase of Exiguobacterium acetylicum (W096/30501), and a process for producing a 5'-nucleotide by the use of an Escherichia coli strain carrying a gene prepared

by imparting a random mutation to the phosphatase gene of Morganella morganii (Japanese Published Unexamined Patent Application No. 37785/97, Japanese Published Unexamined Patent Application No. 201481/98).

5 As the phosphate group donor, various compounds have been studied. For example, methods using the following substances are known: P-nitrophenyl phosphate (Japanese Published Examined Patent Application No. 2985/64), inorganic phosphoric acid (Japanese Published Examined Patent
10 Application No. 1186/67, Japanese Published Examined Patent Application No. 44350/74), polyphosphoric acid (Japanese Published Unexamined Patent Application No. 56390/78), acetyl phosphate (Japanese Published Unexamined Patent Application No. 82098/81), ATP (Japanese Published Unexamined Patent
15 Application No. 230094/88), polyphosphoric acid, phenyl phosphate and carbamyl phosphate (Japanese Published Unexamined Patent Application No. 37785/97), and pyrophosphoric acid (Japanese Published Unexamined Patent Application No. 37785/97, Japanese Published Unexamined
20 Patent Application No. 201481/98).

 However, these methods are not industrially advantageous for the reasons that the substrates to be used are expensive or unstable, the purification steps become complicated because of formation of reaction by-products, etc.
25 As a practical method to meet the economical need, the nucleotide production system by the use of the ATP-regenerating system has been developed. In this system, a microorganism regenerates ATP from AMP or ADP using inorganic phosphoric acid in the course of carbohydrate metabolism. For
30 example, a method has been proposed in which the activity to biosynthesize ATP by metabolizing glucose possessed by an XMP-producing microorganism is used as the ATP-regenerating system. There are publications teaching a method for producing GMP using inexpensive glucose and inorganic
35 phosphoric acid as ATP-regenerating substrates instead of ATP by coupling the above ATP-regenerating system with the XMP

aminase activity of a microorganism having the ability to form GMP from XMP and ATP [Biosci. Biotech. Biochem., 61, 840 (1997)], and a similar method using inosine kinase as an enzyme to produce IMP (Japanese Published Unexamined Patent Application No. 230094/88).

Two kinds of microorganisms are used in a process for producing GMP or IMP which comprises the fermentation step to produce XMP, guanosine or inosine by direct fermentation and the reaction step to enzymatically convert the fermentation product into GMP or IMP.

That is, in the fermentation step which is the first stage of the process, a mutant bred as an XMP-, guanosine- or inosine-producing microorganism (a producing microorganism) is used. In the reaction step of amination or phosphorylation which is the second stage of the process, a microorganism carrying a highly expressed gene encoding a protein having XMP aminase activity or inosine-guanosine kinase activity (a converting microorganism) is used.

ATP which is necessary in the reaction of the second stage is regenerated by the ATP-regenerating activity of not only the converting microorganism used in the second stage, but also the producing microorganism used in the first stage.

Thus, the reaction step of the second stage is a system coupling the XMP aminase activity or the inosine-guanosine kinase activity and the ATP-regenerating activity of two microorganisms.

The outline of the whole process is described below.

First, a producing microorganism is cultured in a medium mainly comprising sugars and nitrogen sources in a large fermentor to form and accumulate XMP, guanosine or inosine. Separately, a converting microorganism is cultured in a small fermentor. When the fermentation of the first stage is completed, the separately cultured converting microorganism is added to the large fermentor to carry out phosphorylation reaction or amination reaction in the presence of an inexpensive energy donor and a phosphate group donor.

The above process utilizing the enzyme reaction is advantageous compared with the chemical phosphorylation method as described above. However, it is still not entirely satisfactory in respect of efficiency because a small fermentor is necessary for culturing a converting microorganism, and the amount of the medium must be reduced at the fermentation step of the first stage in view of the addition of a converting microorganism, which lowers the amount of the desired nucleotide obtained per batch.

10 An object of the present invention is to develop a process for producing a purine nucleotide efficiently in one fermentor.

Summary of the Invention

15 The present inventors pursued the possibility of developing a more excellent process for producing a purine nucleotide in which fermentation to produce a precursor of the nucleotide and reaction to convert said precursor into the nucleotide can be carried out successively using only one microorganism in one fermentor, by introducing a gene of an enzyme capable of synthesizing the purine nucleotide from its precursor into a fermentation microorganism having the ability to produce the precursor of the purine nucleotide and by regulating the expression of the gene in both of the fermentation step and the reaction step. As a result of intensive studies in the pursuit of this possibility, the present invention has been completed.

The present invention relates to the following (1)-(19).

- 30 (1) A process for producing a purine nucleotide which comprises: culturing in a medium a microorganism having the ability to produce a precursor of the purine nucleotide and carrying an introduced DNA which can induce and express an enzyme capable of synthesizing the purine nucleotide from said precursor; allowing said precursor of the purine nucleotide to accumulate in the culture;
- 35

inducing and expressing the enzyme capable of synthesizing the purine nucleotide from said precursor; allowing the purine nucleotide formed from said precursor to accumulate in said culture; and then recovering said purine nucleotide therefrom.

- 5 (2) The process according to the above (1), wherein the precursor of the purine nucleotide is 5'-xanthylic acid, the enzyme capable of synthesizing the purine nucleotide from said precursor is 5'-xanthylic acid aminase, and the purine nucleotide is 5'-guanylic acid.
- 10 (3) The process according to the above (1), wherein the precursor of the purine nucleotide is guanosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-guanylic acid.
- 15 (4) The process according to the above (1), wherein the precursor of the purine nucleotide is inosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-inosinic acid.
- 20 (5) The process according to the above (1), wherein the microorganism belongs to the genus selected from the group consisting of Corynebacterium, Escherichia and Bacillus.
- 25 (6) The process according to the above (1), wherein the microorganism is Corynebacterium ammoniagenes.
- (7) The process according to the above (1), which is characterized in that the enzyme capable of synthesizing the purine nucleotide is induced and expressed by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.
- 30 (8) The process according to the above (7), wherein the non-sugar carbon source is acetic acid or acetate.
- 35 (9) A DNA which can induce and express an enzyme capable of

synthesizing a purine nucleotide from its precursor.

- (10) The DNA according to the above (9), which can induce and express the enzyme capable of synthesizing the purine nucleotide by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.
- (11) The DNA according to the above (10), wherein the non-sugar carbon source is acetic acid or acetate.
- (12) The DNA according to the above (9) or (10), which is pLAC857 or pIGK2.
- (13) A microorganism having the ability to produce a precursor of a purine nucleotide and carrying an introduced DNA which can induce and express an enzyme capable of synthesizing the purine nucleotide from said precursor.
- (14) The microorganism according to the above (13), wherein the precursor of the purine nucleotide is 5'-xanthylic acid, the enzyme capable of synthesizing the purine nucleotide from said precursor is 5'-xanthylic acid aminase, and the purine nucleotide is 5'-guanylic acid.
- (15) The microorganism according to the above (13), wherein the precursor of the purine nucleotide is guanosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-guanylic acid.
- (16) The microorganism according to the above (13), wherein the precursor of the purine nucleotide is inosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-inosinic acid.
- (17) The microorganism according to the above (13), which belongs to the genus selected from the group consisting of Corynebacterium, Escherichia and Bacillus.
- (18) The microorganism according to the above (13), which is Corynebacterium ammoniagenes.
- (19) The microorganism according to the above (18), which is

Corynebacterium ammoniagenes ATCC 6872/pLAC857 (FERM BP-6639) or Corynebacterium ammoniagenes ATCC 6872/pIGK2 (FERM BP-6638).

5 Brief Description of the Drawings

Fig. 1 is a drawing showing the structure of plasmid pLAC857.

Fig. 2 is a drawing showing the structure of plasmid pGUA2.

10 Fig. 3 is a drawing showing the structure of plasmid pIGK2.

The symbols used in the drawings represent the following.

P_L: P_L promoter

15 guaA: XMP aminase gene derived from Escherichia coli

C.glt ORI: Replication origin of Corynebacterium glutamicum

Spc^r: Spectinomycin resistance gene

cI857: Temperature sensitive repressor gene

20 P_{ICL}: Expression-regulating region of the isocitrate lyase gene derived from Corynebacterium glutamicum

T_{ICL}: Terminator of the isocitrate lyase gene derived from Corynebacterium glutamicum

igk: Inosine-guanosine kinase gene derived from Escherichia coli

25 Km^r: Kanamycin resistance gene

Ap^r: Ampicillin resistance gene

E.coli ORI: Replication origin of Escherichia coli

Detailed Description of the Invention

30 The present invention provides a process wherein the fermentation step to produce a precursor of a purine nucleotide by direct fermentation and the reaction step to enzymatically convert the precursor produced in said fermentation step into the purine nucleotide are carried out successively using a
35 single microorganism in one fermentor.

The following three requirements have been found to be

important for the establishment of said process.

The first requirement is that in the fermentation step to produce the precursor of the purine nucleotide by direct fermentation, the expression of a gene encoding an enzyme
5 capable of synthesizing the purine nucleotide from its precursor needs to be suppressed to such a level that the fermentation is not substantially disturbed.

If the expression of said enzyme can not be suppressed, the purine nucleotide is formed and accumulated
10 intracellularly by the activity of said enzyme during the fermentation and the fermentation yield of the purine nucleotide falls for the following reasons.

When GMP is accumulated as the purine nucleotide, the feedback inhibition of the key enzyme in the purine
15 biosynthetic pathway is induced, whereby the production of XMP stops. When IMP is accumulated, a futile cycle is formed with inosine formation, causing waste of ATP. Thus, intracellular formation and accumulation of the purine nucleotide lowers the fermentation yield, which leads to an
20 economical disadvantage.

The second requirement is that in the reaction step to synthesize the purine nucleotide from its precursor, it is needed to sufficiently induce the activity of the enzyme capable of synthesizing the purine nucleotide from its
25 precursor.

The third requirement is that a producing microorganism which has undergone the fermentation and the induction treatment needs to retain a sufficient ATP-regenerating activity and the phosphorylation or amination activity for
30 the conversion reaction, and these activities need to fully function in the reaction step to synthesize the purine nucleotide from its precursor.

The microorganism to be used in the present invention may be a wild strain, a mutant, a fused cell line, a
35 transductant or a recombinant strain obtained by means of recombinant DNA techniques, so long as it has the ability to

produce a precursor of a purine nucleotide and has the ATP-regenerating activity. Preferred microorganisms include those belonging to the genus Corynebacterium, Escherichia or Bacillus, which are useful for nucleic acid
 5 fermentation and amino acid fermentation. Particularly preferred is Corynebacterium ammoniagenes which has a strong ATP-regenerating activity.

The precursors of purine nucleotides include XMP, guanosine, inosine, adenosine, etc.

10 The ATP-regenerating activity refers to the activity to regenerate ATP from AMP or ADP using inorganic phosphoric acid in the process where a microorganism metabolizes sugars as energy donor substrates. This ATP-regenerating system is a part of the carbohydrate metabolism system and the energy
 15 metabolism system such as the glycolytic pathway, the TCA cycle and the electron transport system, and almost all microorganisms have this activity.

Specific examples of the microorganisms to be used in the present invention include the following strains and
 20 mutants derived therefrom.

Corynebacterium ammoniagenes ATCC 6872
Corynebacterium ammoniagenes ATCC 21295
Corynebacterium ammoniagenes ATCC 21477
Corynebacterium glutamicum ATCC 13032
 25 Corynebacterium glutamicum ATCC 14067
Corynebacterium glutamicum ATCC 13869
Escherichia coli ATCC 14948
Escherichia coli ATCC 11303
Escherichia coli ATCC 9637
 30 Bacillus subtilis ATCC 14618

As the enzyme capable of synthesizing a purine nucleotide from its precursor to be used in the present invention, any enzyme capable of synthesizing a purine
 35 nucleotide from its precursor can be used, and suitable examples include XMP aminase, inosine-guanosine kinase,

phosphatase and adenylate kinase.

Examples of the DNAs encoding the above enzymes are given below.

Genes encoding XMP aminase include those derived from
 5 Escherichia coli [Nucleic Acids Res., 13, 1303 (1985)],
Bacillus subtilis [Nucleic Acids Res., 18, 6710 (1990)],
Corynebacterium ammoniagenes (Genbank accession no.
 g2765074), etc.

Genes encoding inosine-guanosine kinase include those
 10 derived from Escherichia coli (WO91/08286), Exiguobacterium
acetylicum (WO96/30501), etc.

Genes encoding phosphatase include those derived from
Morganella morganii (Japanese Published Unexamined Patent
 Application No. 37785/97, Japanese Published Unexamined
 15 Patent Application No. 201481/98), etc.

Genes encoding adenylate kinase include that derived
 from Saccharomyces cerevisiae [J. Biol. Chem., 263, 19468
 (1988)].

The genes encoding the enzymes capable of synthesizing
 20 a purine nucleotide from its precursor can be obtained by a
 known method.

For example, in the case of the gene encoding XMP aminase,
 primers are synthesized based on the sequences at both ends
 of the sequence of an XMP aminase structural gene, and the
 25 XMP aminase structural gene can be obtained by the polymerase
 chain reaction method (PCR method) using the prepared primers
 and the Escherichia coli chromosomal DNA, the Bacillus
subtilis chromosomal DNA or the Corynebacterium ammoniagenes
 chromosomal DNA.

30 In the case of the gene encoding inosine-guanosine
 kinase, primers are synthesized based on the sequences at both
 ends of the sequence of an inosine-guanosine kinase structural
 gene, and the inosine-guanosine kinase structural gene can
 be obtained by the PCR method using the prepared primers and
 35 the Escherichia coli chromosomal DNA or the Exiguobacterium
acetylicum chromosomal DNA. Similarly, by the use of the PCR

method, a phosphatase structural gene can be obtained from the Morganella morganii chromosomal DNA and an adenylate kinase structural gene can be obtained from the Saccharomyces cerevisiae chromosomal DNA.

5 The thus obtained gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor is inserted into an appropriate inducible-expression vector so that the gene is under the control of the transcription and translation signal capable of regulating its induction and
10 expression, whereby a recombinant plasmid which can regulate the expression of said gene can be obtained.

 There is no specific restriction as to the inducible-expression vector, so long as it is replicable in a microorganism to be used and fulfills the following three
15 conditions.

 First, the expression of the gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor can be repressed to a level where fermentation is not substantially disturbed in the fermentation step to produce
20 the precursor of the purine nucleotide by direct fermentation.

 Secondly, the activity of the enzyme capable of synthesizing the purine nucleotide from its precursor is sufficiently induced by the induction treatment to be carried out prior to the reaction step to synthesize the purine
25 nucleotide from its precursor.

 Thirdly, said induction method is a method which allows a producing microorganism to retain a sufficient ATP-regenerating activity and the converting activity after the induction treatment.

30 Examples of the vectors which fulfill the above three conditions include pPAC31 which contains the P_L promoter/cI857 repressor gene and is induced at a high temperature (WO98/12343), pBB1 which contains the lac promoter/lacIts repressor gene and is induced at a high temperature [Gene,
35 70, 415 (1988)], pRK248cIts which contains the P_L promoter/cI857 repressor gene and is induced at a high pH [Gene,

97, 125 (1991)], pOSEX2 which contains the proU expression-regulating region and is induced under a high osmotic pressure [Gene, 151, 137 (1994)], pTrc99A which contains the trc promoter/lacI^q repressor gene and is induced
 5 with isopropyl- β -D-thiogalactoside (IPTG) [Gene, 69, 301 (1988)], pAL9181 which contains the araBAD promoter/araC repressor gene and is induced with L-arabinose [Appl. Microbiol. Biotechnol., 37, 205 (1992)] and vectors induced by changing the carbon source from sugars to non-sugars.
 10 These vectors are inducible-expression vectors constructed for Escherichia coli.

Further, vectors obtained by modifying the transcription-translation signal region related to the regulation of the expression in the above inducible-
 15 expression vectors by mutation techniques or recombinant DNA techniques can be used as well.

When these known inducible-expression vectors or further improved vectors are used in host cells other than Escherichia coli, a replication origin which functions in the
 20 host is inserted therein. For example, when Corynebacterium ammoniagenes is employed as a host, a replication origin of a plasmid derived from Corynebacterium glutamicum which functions in Corynebacterium ammoniagenes or the like is inserted into said vector.

25 The plasmids derived from Corynebacterium glutamicum include pCG1 (Japanese Published Unexamined Patent Application No. 134500/82), pCG2 (Japanese Published Unexamined Patent Application No. 35197/83), pCG4 (Japanese Published Unexamined Patent Application No. 183799/82),
 30 PAM330 (Japanese Published Unexamined Patent Application No. 67699/83), and pAG1, pAG3, pAG14 and pAG50 (Japanese Published Unexamined Patent Application No. 166890/87).

The preferred vectors functioning in Corynebacterium include a plasmid vector capable of being induced by raising
 35 the temperature which is prepared by ligating the P_L promoter/cI857 gene carried by pPAC31 which is a vector induced

at a high temperature in Escherichia coli with a vector autonomously replicable in Corynebacterium, vector pCEX2 capable of being induced with a non-sugar carbon source such as acetic acid (Japanese Published Unexamined Patent Application No. 224259/91), etc.

On the other hand, when the transcription-translation signal related to the regulation of gene expression in the inducible-expression vectors does not function in a microorganism to be used, or when it functions but the above three requirements are not sufficiently fulfilled, it is necessary to improve said transcription-translation signal region by mutation techniques or recombinant DNA techniques so that the above three requirements can be fulfilled, or to develop a new system of induction and expression applicable to said microorganism. In the former case, the improvement can be carried out, for example, by site-directed mutagenesis referring to a transcription-translation signal sequence known for the microorganism to be used. In the latter case, the new system can be developed and constructed according to the method of developing the above general inducible-expression systems constructed for Escherichia coli, etc.

Preferred examples of the microorganisms carrying the inducible-expression system include Corynebacterium ammoniagenes strains, etc., which were respectively developed using, as the gene-inducing and expressing system, a temperature-inducible plasmid vector which is prepared by ligating the P_L promoter/cI857 gene carried by pPAC31 which is a vector induced at a high temperature in Escherichia coli with a vector autonomously replicable in Corynebacterium, and pCEX2 capable of regulating the expression by addition of inexpensive acetic acid.

In the present invention, the gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor may exist in a vector plasmid or may be integrated into the chromosome of a host microorganism, so long as the above three requirements are fulfilled. That is, either a strain carrying

a plasmid containing the gene or a strain in which the gene has been integrated into the chromosome can be used, so long as the expression of said gene can be appropriately regulated.

The inducible-expression plasmid containing the gene
5 encoding the enzyme capable of synthesizing a purine nucleotide from its precursor can be introduced into a microorganism which produces the precursor of the purine nucleotide by using the protoplast method, the electric pulse method, the calcium chloride method, and conventional methods
10 described in Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter abbreviated as Molecular Cloning, Second Edition), etc.

For example, when a bacterium belonging to the genus
15 Corynebacterium is used as the host microorganism, the protoplast method (Japanese Published Unexamined Patent Application No. 183799/82) and the electric pulse method (Japanese Published Unexamined Patent Application No. 207791/90) are particularly effective. When Escherichia coli
20 is used as the host microorganism, the calcium chloride method [J. Mol. Biol., 53, 159 (1970)], etc. can also be employed.

The enzyme capable of synthesizing a purine nucleotide from its precursor can be induced and expressed by culturing the thus obtained transformant of the present invention
25 carrying the introduced gene encoding the enzyme capable of synthesizing the purine nucleotide from its precursor in an ordinary medium containing carbon sources, nitrogen sources and inorganic substances, and additionally, trace organic nutrients, as may be required, to form and accumulate the
30 precursor of the purine nucleotide, and then subjecting the resulting culture to the induction treatment such as heating or addition of acetic acid.

As the carbon source in the medium to be used in the above fermentation step, any carbon source which can be
35 assimilated by said microorganism can be used. Examples of suitable carbon sources are carbohydrates such as glucose,

fructose, sucrose, molasses, blackstrap molasses and starch hydrolyzate, alcohols such as ethanol, glycerin and sorbitol, organic acids such as pyruvic acid and lactic acid, and amino acids such as glycine, alanine, glutamic acid and aspartic acid. The preferable concentration thereof is in the range of 5-30%.

Examples of the nitrogen sources include ammonia, various inorganic and organic ammonium salts such as ammonium chloride, ammonium sulfate, ammonium nitrate, ammonium carbonate, ammonium acetate and ammonium phosphate, urea, various amino acids, peptone, NZ amine, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, fish meal and digested matters thereof.

Examples of the inorganic substances include potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium sulfate, magnesium phosphate, sodium chloride, ferrous sulfate, manganese sulfate, zinc sulfate and calcium carbonate.

When the microorganism employed requires particular nutrients such as amino acids, nucleic acids and vitamins for the growth, these substances are added to the medium in appropriate amounts.

Culturing is carried out under aerobic conditions, for example, by shaking culture or spinner culture under aeration. The optimum temperature is usually 26-37°C. The culturing period is usually 1-5 days.

The induction treatment for the expression of the gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor is carried out under conditions appropriate for the vector used; for example, the vectors mentioned below are preferably treated under the following conditions.

pPAC31 or pBB1: spinner culture under aeration at 37-42°C for 1-24 hours
pRK248cIts: for 1-24 hours at pH 9
pOSEX2: for 1-24 hours in the presence of 50-300 mmol/l

NaCl

pTrc99A: for 1-24 hours in the presence of 0.1-0.5 mmol/l
IPTG

pAL9181: for 1-24 hours with addition of 0.2% L-
arabinose

pCEX2: for 1-24 hours with addition of 0.1-2% ammonium
acetate or sodium acetate

It is preferred to add a surfactant in the reaction step
to synthesize a purine nucleotide from its precursor.

As the surfactant, those which promote the permeation
of a purine nucleotide through a cell membrane are preferred.
Suitable examples are cationic surfactants such as
polyoxyethylene stearylamine (e.g., Nymeen S-215, NOF
Corporation), cetyltrimethylammonium bromide, Cation FB and
Cation F2-40E, anionic surfactants such as sodium oleylamide
sulfate, Newrex TAB and Rapizole 80, and amphoteric
surfactants such as polyoxyethylene sorbitan monostearate
(e.g., Nonion ST221). The surfactant is usually used at a
concentration of 0.1-50 mg/ml, preferably 1-20 mg/ml.

The reaction in the step to synthesize a purine
nucleotide from its precursor is carried out at pH 6-8 at
20-40°C for 1-48 hours.

After the reaction is completed, the purine nucleotide
formed and accumulated in the reaction mixture can be recovered
by known methods such as a method comprising removing microbial
cells and crystallizing the nucleotide by concentration, the
activated carbon treatment and the ion exchange resin method
[Isao Endo, et al., Kagakukogakkai (The Society of Chemical
Engineers, Japan) (ed.), Bioseparation Process Binran
(Handbook of Bioseparation Process), Kyoritsu Shuppan
(1996)].

Certain embodiments of the present invention are
illustrated in the following examples, which are not intended
to limit the scope of the present invention. The gene
engineering procedures were carried out according to the
methods described in Molecular Cloning, Second Edition,

unless otherwise specified.

Example 1 Construction of an XMP-Producing Strain of

Corynebacterium ammoniagenes Carrying the XMP Aminase
5 Gene of Escherichia coli under the Control of P_L Promoter
and Production of GMP by the Strain

(1) Construction of Inducible-Expression Plasmid pLAC857
Capable of Regulating the Expression of the XMP Aminase
Gene by the Shift in Temperature

10 A thermal inducible-expression plasmid pLAC857 was
constructed from a known plasmid pPLA66 through the following
two steps. pPLA66 is a plasmid which expresses XMP aminase
at a high level and which was constructed by ligating an XMP
aminase gene at a position downstream of the P_L promoter and
15 the SD sequence of trpL [Biosci. Biotech. Biochem., 61, 840
(1997)].

A temperature sensitive repressor gene cI857 was
inserted into plasmid pPLA66 in the following manner.

Plasmid pPLA66 (1 μ g) was cleaved with EcoRI (5 units)
20 and BglIII (5 units). The cleaved fragments were separated by
agarose gel electrophoresis, and a DNA fragment containing
the P_L promoter and the region of the XMP aminase gene (guaA
gene) derived from Escherichia coli was recovered from the
gel using QIAEXII (QIAGEN CO., LTD.).

25 Plasmid pPAC31 carrying the cI857 gene (WO98/12343) (1
 μ g) was cleaved with EcoRI (5 units) and BamHI (5 units). The
cleaved fragments were separated by agarose gel
electrophoresis, and a DNA fragment containing the cI857 gene,
an ampicillin resistance gene and the replication origin
30 derived from Escherichia coli was recovered from the gel.

The DNA fragment containing said gene and the previously
prepared DNA fragment containing the guaA gene were ligated
by the use of a ligation kit (Takara Shuzo Co., Ltd.).

Escherichia coli JM109 (Takara Shuzo Co., Ltd.) was
35 transformed using the ligation mixture and then spread on L
agar medium containing 100 μ g/ml ampicillin to obtain an

ampicillin-resistant transformant.

A plasmid DNA was extracted from the obtained transformant by the alkali bacteriolysis method.

5 The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that plasmid pLA857 comprising the XMP aminase gene, the *ci857* gene, the ampicillin resistance gene and the replication origin of the plasmid autonomously replicable in Escherichia coli in the region under the control of the P_L promoter was obtained.

10 The replication origin of the plasmid autonomously replicable in Corynebacterium was inserted into plasmid pLA857 in the following manner.

Plasmid pLA857 (1 μ g) was cleaved with PstI (5 units) at the only PstI-cleavage site existing thereon. The cleaved
15 fragment was separated by agarose gel electrophoresis and recovered from the gel, whereby a PstI-cleaved fragment of pLA857 was obtained.

Plasmid vector pCG116 replicable in Corynebacterium ammoniagenes (Japanese Published Unexamined Patent
20 Application No. 265892/89) (1 μ g) was cleaved with PstI (5 units). After dephosphorylation of the DNA was effected by alkali phosphatase treatment to prevent rebinding, extraction with phenol and precipitation with ethanol were carried out, whereby a PstI-cleaved fragment of pCG116 was obtained.

25 The above-obtained PstI-cleaved fragment of pLA857 and PstI-cleaved fragment of pCG116 were ligated using the above ligation kit.

Corynebacterium ammoniagenes ATCC 6872 was transformed using 1 μ g of the DNA obtained by the ligation treatment by
30 means of the electric pulse method [Appl. Microbiol. Biotechnol., 30, 283 (1989)] and then spread on A agar medium [0.5% glucose, 1% peptone, 0.5% meat extract, 0.5% yeast extract, 0.25% sodium chloride, 1.5% agar, 10 mg/l adenine and 10 mg/l guanine (pH 7.2)] containing 100 μ g/ml
35 spectinomycin.

A plasmid DNA was extracted from the obtained

spectinomycin-resistant transformant by the alkali bacteriolysis method.

The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that the obtained
5 transformant carried plasmid pLAC857 having the desired structure shown in Fig. 1.

Corynebacterium ammoniagenes ATCC 6872/pLAC857 carrying pLAC857 was deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial
10 Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305-0046 Japan, on February 5, 1999 with accession number FERM BP-6639 under the Budapest Treaty.

(2) Measurement of the XMP Aminase Activity of a Strain
15 Prepared by Introducing pLAC857 into FERM BP-1261 Strain
Plasmid pLAC857 was extracted from Corynebacterium ammoniagenes ATCC 6872/pLAC857 (FERM BP-6639) by the alkali bacteriolysis method.

An XMP-producing strain of Corynebacterium
20 ammoniagenes, FERM BP-1261 (Japanese Patent No. 2618383: adenine-leaky requiring and guanine-requiring), was transformed using said plasmid by the above electric pulse method.

A plasmid DNA was extracted from the obtained
25 spectinomycin-resistant transformant by the alkali bacteriolysis method.

The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that the obtained transformant carried pLAC857.

30 The XMP-producing strain FERM BP-1261 carrying pLAC857 was cultured by shaking in A medium (a medium prepared by eliminating agar from A agar medium) containing 100 μ g/ml spectinomycin at 30°C and 37°C, respectively for 24 hours.

After the culturing was completed, cells were obtained
35 from each culture by centrifugation.

The obtained cells were washed twice with 100 mmol/l

Tris-HCl (pH 7.0) and suspended in 10 ml of the same buffer.

To the resulting suspension was added 10 g of glass beads (Shinmaru Enterprises Co., Ltd., 0.1-0.2 ϕ), followed by disruption using a homogenizer (Nippon Seiki Co., Ltd.) under ice-cooling for 10 minutes.

The obtained suspension was centrifuged (14000 x g) at 4°C for 10 minutes, and the supernatant was recovered as a cell extract.

To 1.15 ml of a reaction mixture [160 mmol/l Tris-HCl (pH 8.6), 12 mmol/l ATP Na₂·3H₂O, 16 mmol/l MgSO₄·7H₂O and 40 mmol/l (NH₄)₂SO₄] containing the cell extract previously heated to 42°C was added 0.1 ml of 0.3 mol/l XMP to start reaction at 42°C. Fifteen minutes later, 3.9 ml of 3.5% perchloric acid was added to the reaction mixture to stop the reaction.

The reaction mixture was centrifuged at 3000 rpm for 10 minutes, and the absorbance of the supernatant at 290 nm was measured. The specific activity per milligram of protein was calculated taking the activity to form 1 μ mol of GMP in one minute as one unit (U). The amount of protein was determined using a protein assay kit (BioRad Laboratories).

The results are shown in Table 1. No activity was detected in the cells cultured at 30°C, while the activity was detected in the cells cultured at 37°C. These results indicate that the expression of the XMP aminase gene is under the control of the P_L promoter in FERM BP-1261 strain carrying pLAC857, and the activity of said enzyme can be regulated by shifting the temperature.

30

Table 1

Culturing temperature	Specific activity (μ mol/min/mg protein)
30°C	Not detected
37°C	0.25

(3) Production of GMP by the XMP-Producing Strain FERM

BP-1261 Carrying pLAC857

FERM BP-1261 strain carrying pLAC857 was cultured on A agar medium containing 20 μ g/ml streptomycin at 30°C for 2 days. The obtained cells were inoculated into a 250-ml
 5 Erlenmeyer flask containing 60 ml of C seed medium [5% glucose, 1% yeast extract, 1% peptone, 0.25% NaCl, 0.3% urea, 150 mg/l adenine and 150 mg/l guanine (pH 7.2)] containing 20 μ g/ml streptomycin, followed by shaking culture at 30°C for 24 hours.

The whole of the obtained culture was inoculated into
 10 a 2-l fermentor containing 0.94 l of D seed medium [8.8% glucose, 1.7% meat extract, 1.7% peptone, 0.167% KH_2PO_4 , 0.167% K_2HPO_4 , 0.167% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 333 mg/l adenine, 350 mg/l guanine, 33 mg/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 17 mg/l $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 6.7 mg/l $\text{MnSO}_4 \cdot 4-6\text{H}_2\text{O}$, 25 mg/l β -alanine, 33 mg/l L-cysteine, 167 μ g/l biotin, 1.3 mg/l
 15 $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ and 8.3 mg/l thiamine (pH 7.2)], followed by culturing with stirring (600 rpm) and aeration (1 l/min) at 30°C for 24 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

The obtained culture (120 ml) was inoculated into a 2-l
 20 fermentor containing 0.88 l of F fermentation medium [8% glucose, 1.67% orthophosphoric acid, 1.29% KOH, 1.2% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 123 mg/l $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 24.6 mg/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 12.3 mg/l $\text{MnSO}_4 \cdot 4-6\text{H}_2\text{O}$, 12.3 mg/l $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 18.5 mg/l β -alanine, 24.6 mg/l L-cysteine, 6.2 mg/l nicotinamide, 24.6 mg/l histidine,
 25 185 μ g/l biotin, 2.5 mg/l $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 203 mg/l adenine and 10 mg/l guanine (pH 7.2)], followed by culturing with stirring (600 rpm) and aeration (1 l/min) at 28°C for 44 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

After the culturing was completed, the amounts of XMP
 30 and GMP accumulated in the culture supernatant were determined by HPLC in the following manner.

Conditions for HPLC analysis

Column: Asahipak GS-320H (Asahi Chemical Industry Co., Ltd.)

35 Eluent: 0.2 mol/l NaH_2PO_4 (pH 3.0)

Flow rate: 1 ml/min

Detection: UV 254 nm

The amounts of XMP and GMP accumulated were determined by measuring the absorbance at UV 254 nm and comparing the absorbance with the standard.

5 As the result of HPLC analysis, it was found that XMP was formed and accumulated in an amount of 27.2 g/l, but GMP was not detected.

To induce and express the XMP aminase gene, the culture broth was heated to 40°C, and kept at the same temperature with stirring (600 rpm) and aeration (1 l/min) for 6 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

To the XMP fermentation broth subjected to the above thermal induction treatment were added 2.5% glucose, 10 g/l phytic acid, 4.4 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 9.36 g/l Na_2HPO_4 , 96.9 mg/l adenine and 10 g/l Nymeen S-215, and the resulting mixture was subjected to reaction with stirring (600 rpm) and aeration (1 l/min) at 40°C for 24 hours, during which the pH was kept at 7.4 with 5.5 mol/l aqueous ammonia.

20 After the reaction was completed, the amount of GMP accumulated in the supernatant of the reaction mixture was determined under the above HPLC analysis conditions. As the result, it was found that GMP was formed and accumulated in an amount of 20.8 g/l.

25

Example 2 Construction of an XMP-Producing Strain of Corynebacterium ammoniagenes Carrying the XMP Aminase Gene of Corynebacterium ammoniagenes under the Control of the Promoter of an Isocitrate Lyase Gene and Production of GMP by the Strain

30

(1) Amplification and Cloning of the XMP Aminase Gene by PCR

Isolation of the XMP aminase gene of Corynebacterium ammoniagenes was carried out by PCR based on the nucleotide sequence in the following manner.

35

First, the oligonucleotides shown in SEQ ID NOS: 1 and 2 which are located at both ends of the XMP aminase gene and

which respectively have the cleavage sites for the restriction enzymes AflIII and BamHI were synthesized. The chromosomal DNA of Corynebacterium ammoniagenes ATCC 6872 to be used as the template was prepared according to the method for preparing
5 protoplasts by treating cells cultured in the presence of glycine with lysozyme and achromopeptidase (Japanese Published Unexamined Patent Application No. 225776/94).

The obtained chromosomal DNA (0.1 μ g), the above oligonucleotides (0.25 μ mol/l each) as the primers and Taq
10 DNA polymerase (Takara Shuzo Co., Ltd., 2.5 units) were added to 0.1 ml of 10 mmol/l Tris-HCl buffer (pH 8.3) comprising 200 μ mol/l each of dATP, dCTP, dGTP and dTTP, 50 mmol/l potassium chloride, 1.5 mmol/l magnesium chloride and 0.0001% gelatin, and the resulting mixture was subjected to PCR.

15 PCR was carried out by repeating 10 times a reaction cycle in which reaction is conducted at 94°C for 90 seconds, at 50°C for 120 seconds and at 72°C for 120 seconds; repeating 10 times a reaction cycle in which reaction is conducted at 94°C for 90 seconds, at 40°C for 120 seconds and at 72°C for
20 120 seconds; and further repeating 20 times a reaction cycle in which reaction is conducted at 94°C for 90 seconds, at 40°C for 120 seconds and at 72°C for 180 seconds; and then conducting reaction at 72°C for 360 seconds.

The obtained reaction mixture was subjected to agarose
25 gel electrophoresis, whereby the desired DNA fragment of about 1.6 kb was recovered.

Said DNA fragment was cleaved with the restriction enzymes AflIII (5 units) and BamHI (5 units), and a cleaved fragment of about 1.6 kb whose ends were respectively treated
30 with AflIII and BamHI was isolated and recovered by agarose gel electrophoresis.

(2) Construction of Inducible-Expression Plasmid pGUA2

Capable of Regulating the Expression of the XMP Aminase
35 Gene with a Carbon Source

A plasmid which can regulate the expression of the XMP

aminase gene with a carbon source was constructed in the following manner using inducible-expression vector pCEX2 (Japanese Published Unexamined Patent Application No. 224259/91).

5 pCEX2 is a vector containing the expression-regulating region and the transcription termination signal sequence of the isocitrate lyase gene of Corynebacterium glutamicum, and the expression of an exogenous gene inserted into the multicloning site thereon is suppressed in the presence of
10 a sugar and is induced in the presence of a non-sugar such as acetic acid.

 pCEX2 vector DNA (1 μ g) was partially cleaved with AflII (0.5 unit) and then cleaved with BamHI (5 units). Then, a DNA fragment of 7.6 kb containing the expression-regulating
15 region and the transcription termination signal region of the isocitrate lyase gene, a spectinomycin resistance gene and the replication origin of the plasmid autonomously replicable in Corynebacterium glutamicum was isolated and recovered by agarose gel electrophoresis.

20 Said DNA fragment and the PCR-amplified fragment of the XMP aminase gene obtained in the above Example 2 (1) were ligated to obtain a ligated DNA.

Corynebacterium ammoniagenes ATCC 6872 was transformed using said ligated DNA (1 μ g) by the electric pulse method,
25 and then spread on A agar medium containing 100 μ g/ml spectinomycin.

 A plasmid DNA was extracted from the obtained spectinomycin-resistant transformant by the alkali bacteriolysis method.

30 The plasmid DNA was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that the obtained transformant carried plasmid pGUA2 having the desired structure shown in Fig. 2.

35 (3) Measurement of the XMP Aminase Activity of a Strain Prepared by Introducing pGUA2 into FERM Bi-1261 Strain

Plasmid pGUA2 was extracted from Corynebacterium ammoniagenes ATCC 6872 carrying pGUA2 by the alkali bacteriolysis method.

5 An XMP-producing strain of Corynebacterium ammoniagenes, FERM BP-1261 (adenine-leaky requiring and guanine-requiring), was transformed using said plasmid by the electric pulse method.

A plasmid DNA was extracted from the obtained spectinomycin-resistant transformant by the alkali
10 bacteriolysis method.

The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that the transformant carried pGUA2.

The XMP-producing strain FERM BP-1261 carrying pGUA2
15 was cultured by shaking in two kinds of media, i.e., A medium containing 100 μ g/ml spectinomycin and a medium prepared by replacing glucose in said medium by ammonium acetate, separately, at 30°C for 24 hours.

Cells were obtained from the resulting cultures to
20 prepare cell extracts in the same manner as in Example 1 (2).

The XMP aminase activity in each of the extracts was measured according to the method described in Example 1 (2).

The results are shown in Table 2.

Only an extremely low level of activity was detected
25 in the cells cultured using glucose as the carbon source, while a high level of activity was detected in the cells cultured using 2% ammonium acetate as the carbon source.

These results indicate that the expression of the XMP
30 aminase gene is under the control of the promoter of the isocitrate lyase gene in FERM BP-1261 carrying pGUA2, and the activity of said enzyme can be regulated by changing the carbon source.

Table 2

Carbon source	Specific activity ($\mu\text{mol/min/mg protein}$)
Glucose	0.05
Ammonium acetate	0.38

(4) Production of GMP by the Strain Prepared by Introducing pGUA2 to XMP-Producing Strain FERM BP-1261

5 XMP fermentation was carried out using FERM BP-1261 strain carrying pGUA2 under the same culturing conditions as in Example 1 (3). After the culturing was completed, the amounts of XMP and GMP formed and accumulated in the culture supernatant were determined in the same manner as in Example 10 1 (3).

As the result, the amount of XMP accumulated was found to be 18.4 g/l. GMP was not detected.

After the fermentation was completed, in order to induce and express the XMP aminase gene, ammonium acetate was added 15 to the fermentation broth to a final concentration of 2%, followed by culturing with stirring (600 rpm) and aeration (1 l/min) for 10 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

To the culture subjected to the above induction 20 treatment with ammonium acetate were added 2.5% glucose, 10 g/l phytic acid, 4.4 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 9.36 g/l Na_2HPO_4 , 96.9 mg/l adenine and 10 g/l Nymeen S-215, and the resulting mixture was subjected to reaction with stirring (600 rpm) and aeration (1 l/min) at 40°C for 24 hours, during which the pH was kept 25 at 7.4 with 5.5 mol/l aqueous ammonia.

After the reaction was completed, the amount of GMP accumulated in the supernatant of the reaction mixture was determined according to the method described in Example 1 (3).

30 It was found that GMP was formed and accumulated in an amount of 14.4 g/l in the reaction mixture.

Example 3 Construction of an Inosine-Producing Strain of

Corynebacterium ammoniagenes Carrying the Inosine-Guanosine Kinase Gene of Escherichia coli under the Control of the Promoter of an Isocitrate Lyase Gene and Production of IMP by the Strain

5 (1) Amplification and Cloning of the Inosine-Guanosine Kinase Gene by PCR

Isolation of the inosine-guanosine kinase gene of Escherichia coli was carried out by PCR based on the known nucleotide sequence (WO91/08286) in the following manner.

10 The oligonucleotides shown in SEQ ID NOS: 3 and 4 which are located at both ends of the inosine-guanosine kinase gene and which respectively have the cleavage sites for the restriction enzymes AflII and BamHI were synthesized.

Plasmid pBM2 carried by Escherichia coli HM70/pBM2
15 (WO91/08286) was used as the template of the inosine-guanosine kinase gene.

The above plasmid DNA (0.1 μ g), the above oligonucleotides (0.25 μ mol/l each) as the primers and Taq DNA polymerase (Takara Shuzo Co., Ltd., 2.5 units) were added
20 to 0.1 ml of 10 mmol/l Tris-HCl buffer (pH 8.3) comprising 200 μ mol/l each of dATP, dCTP, dGTP and dTTP, 50 mmol/l potassium chloride, 1.5 mmol/l magnesium chloride and 0.0001% gelatin, and the resulting mixture was subjected to PCR.

PCR was carried out by repeating 10 times a reaction
25 cycle in which reaction was conducted at 94°C for 90 seconds, at 50°C for 120 seconds and at 72°C for 120 seconds; repeating 10 times a reaction cycle in which reaction was conducted at 94°C for 90 seconds, at 40°C for 120 seconds and at 72°C for 120 seconds; further repeating 20 times a reaction cycle in
30 which reaction was conducted at 94°C for 90 seconds, at 40°C for 120 seconds and at 72°C for 180 seconds; and then conducting reaction at 72°C for 360 seconds.

The obtained PCR reaction product was ligated with vector pT-Adv which is a vector for the cloning of a PCR product
35 (Clontech Co., Ltd.).

Escherichia coli DH5 α was transformed using 1 μ g of

the DNA obtained by said ligation treatment, and then spread on L agar medium containing 100 μ g/ml ampicillin.

Plasmid pT-AI was extracted from the obtained ampicillin-resistant transformant by the alkali
5 bacteriolysis method.

The structure of the plasmid pT-AI was analyzed using various restriction enzymes, whereby it was confirmed that this plasmid contained the inosine-guanosine kinase gene (1.3 kb), an ampicillin resistance gene, a kanamycin resistance
10 gene and the replication origin of the plasmid autonomously replicable in Escherichia coli.

(2) Construction of Inducible-Expression Plasmid pIGK2
Capable of Regulating the Expression of the Inosine-
15 Guanosine Kinase Gene with a Carbon Source

A plasmid which can regulate the expression of the inosine-guanosine kinase gene with a carbon source was constructed in the following manner using inducible-expression vector pCEX2 (Japanese Published Unexamined Patent
20 Application No. 224259/91).

pCEX2 vector DNA (1 μ g) was cleaved with KpnI (5 units) and a DNA fragment of 7.6 kb containing the expression-regulating region and the transcription termination signal region of the isocitrate lyase gene, a spectinomycin
25 resistance gene and the replication origin of the plasmid autonomously replicable in Corynebacterium glutamicum was isolated and recovered by agarose gel electrophoresis.

The plasmid pT-AI containing the inosine-guanosine kinase gene obtained in Example 3 (1) (1 μ g) was cleaved with
30 KpnI (5 units), followed by dephosphorylation.

This KpnI-cleaved DNA fragment and the above KpnI-cleaved fragment of pCEX2 were ligated.

Escherichia coli DH5 α was transformed using the obtained ligation mixture, and then spread on L agar medium
35 containing 100 μ g/ml ampicillin to obtain an ampicillin-resistant transformant.

A plasmid was extracted from the obtained transformant by the alkali bacteriolysis method.

The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that plasmid pIGK2
5 having the desired structure shown in Fig. 3 was obtained.

Corynebacterium ammoniagenes ATCC 6872 was transformed using this plasmid (1 μ g) by the electric pulse method and then spread on A agar medium containing 100 μ g/ml spectinomycin.

10 A plasmid DNA was extracted from the obtained spectinomycin-resistant transformant by the alkali bacteriolysis method and it was confirmed that the transformant carried pIGK2.

Corynebacterium ammoniagenes ATCC 6872/pIGK2 carrying
15 pIGK2 was deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305-0046 Japan, on February 5, 1999 with accession number FERM BP-6638 under the Budapest Treaty.

20

(3) Measurement of the Inosine-Guanosine Kinase Activity of a Strain Prepared by Introducing pIGK2 into FERM BP-2217 Strain

Plasmid pIGK2 was extracted from Corynebacterium
25 ammoniagenes ATCC 6872/pIGK2 (FERM BP-6638) by the alkali bacteriolysis method.

An inosine-producing strain of Corynebacterium
ammoniagenes, FERM BP-2217 (Japanese Patent No. 2578496: adenine-leaky requiring and guanine-requiring), was
30 transformed using said plasmid by the electric pulse method.

A plasmid DNA was extracted from the obtained spectinomycin-resistant transformant by the alkali bacteriolysis method.

The plasmid was cleaved with various restriction enzymes
35 and analyzed, whereby it was confirmed that the obtained transformant carried pIGK2.

The inosine-producing strain FERM BP-2217 carrying pIGK2 was cultured in two kinds of media, i.e., A medium containing 100 μ g/ml spectinomycin and a medium prepared by replacing glucose in said medium by ammonium acetate, separately, at 30°C for 24 hours.

Cells were obtained from the resulting cultures to prepare cell extracts according to the method described in Example 1 (2).

The inosine-guanosine kinase activity in each of the extracts was measured in the following manner.

To 0.1 ml of a reaction mixture [100 mmol/l HEPES buffer (pH 7.2), 10 mmol/l MgSO_4 , 50 mmol/l KCl, 1 mmol/l ATP and 1 mmol/l inosine] previously heated to 30°C was added 0.01 ml of the cell extract, followed by reaction at 30°C for about 30 minutes.

During the reaction, the reaction mixture was sampled at intervals and the samples taken were diluted 20-fold with 0.2 mol/l NaH_2PO_4 (adjusted to pH 2.6 with H_3PO_4) to stop the reaction.

The amounts of inosine and IMP in the diluted samples were determined by HPLC analysis.

Conditions for HPLC analysis

Column: Asahipak GS-320H (Asahi Chemical Industry Co., Ltd.)

Eluent: 0.2 mol/l NaH_2PO_4 (pH 2.6)

Flow rate: 1 ml/min

Detection: UV 254 nm

The amounts of inosine and IMP accumulated were determined by measuring the absorbance at UV 254 nm and comparing the absorbance with the standard. The specific activity per milligram of protein was calculated taking the activity to form 1 μ mol of IMP in one minute as one unit (U).

The amount of protein was determined using a protein assay kit (BioRad Laboratories).

The results are shown in Table 3. Only an extremely low level of activity was detected in the cells cultured using

glucose as the carbon source, while a high level of activity was detected in the cells cultured using 2% ammonium acetate as the carbon source. These results indicate that the expression of the inosine-guanosine kinase gene is under the control of the promoter of the isocitrate lyase gene in FERM BP-2217 carrying pIGK2, and the activity of said enzyme can be regulated by changing the carbon source.

Table 3

Carbon source	Specific activity ($\mu\text{mol/min/mg protein}$)
Glucose	0.02
Ammonium acetate	0.34

10

(4) Production of IMP by the Inosine-Producing Strain FERM BP-2217 Carrying pIGK2

FERM BP-2217 strain carrying pIGK2 was cultured on A agar medium containing 20 $\mu\text{g/ml}$ streptomycin at 30°C for 2 days.

After the culturing was completed, the obtained cells were inoculated into a 250-ml Erlenmeyer flask containing 60 ml of CI seed medium [5% glucose, 1% yeast extract, 1% peptone, 0.25% NaCl, 0.25% urea, 300 mg/l adenine and 100 mg/l guanine (pH 7.2)] containing 20 $\mu\text{g/ml}$ streptomycin, followed by shaking culture at 30°C for 24 hours.

The whole of the obtained culture was inoculated into a 2-l fermentor containing 0.94 l of DI seed medium [7% glucose, 1% meat extract, 1% peptone, 0.1% KH_2PO_4 , 0.1% K_2HPO_4 , 0.1% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 300 mg/l adenine, 300 mg/l guanine, 10 mg/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 10 mg/l $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 10 mg/l $\text{MnSO}_4 \cdot 4-6\text{H}_2\text{O}$, 16 mg/l β -alanine, 20 mg/l L-cysteine, 30 $\mu\text{g/l}$ biotin, 2 mg/l $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ and 6 mg/l thiamine (pH 7.2)], followed by culturing with stirring (600 rpm) and aeration (1 l/min) at 30°C for 24 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

The obtained culture (120 ml) was inoculated into a 2-l

fermentor containing 0.88 l of FI fermentation medium [8% glucose, 2.07% CSL, 0.21% KH_2PO_4 , 0.21% K_2HPO_4 , 0.43% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 105 mg/l $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 10.4 mg/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 20.7 mg/l $\text{MnSO}_4 \cdot 4-6\text{H}_2\text{O}$, 5.2 mg/l $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 10.4 mg/l calcium pantothenate, 20.7 mg/l L-cysteine, 5.2 mg/l nicotinic acid, 93.8 $\mu\text{g/l}$ biotin, 0.51 mg/l $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ and 313 mg/l adenine (pH 7.2)], followed by culturing with stirring (600 rpm) and aeration (1 l/min) at 28°C for 44 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

10 After the culturing was completed, the amounts of inosine and IMP formed and accumulated in the culture supernatant were determined according to the method described in Example 3 (3).

The amount of inosine formed and accumulated in the culture supernatant was 23.1 g/l and IMP was not detected.

After the culturing was completed, in order to induce and express the inosine-guanosine kinase gene, ammonium acetate was added to the obtained culture to a final concentration of 2%, followed by culturing with stirring (600 rpm) and aeration (1 l/min) for 10 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

To the obtained culture were added 2.5% glucose, 10 g/l phytic acid, 4.4 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 9.36 g/l Na_2HPO_4 , 96.9 mg/l adenine and 10 g/l Nymeen S-215, and the resulting mixture was subjected to reaction with stirring (600 rpm) and aeration (1 l/min) at 40°C for 24 hours, during which the pH was kept at 7.4 with 5.5 mol/l aqueous ammonia.

After the reaction was completed, the amount of IMP accumulated in the supernatant of the reaction mixture was determined according to the method described in Example 3 (3).

It was found that IMP was formed and accumulated in an amount of 37.7 g/l in the reaction mixture.

Sequence Listing

<110> Yutaka TAKANO

Masato IKEDA

5 Tatsuro FUJIO

<120> Process for producing purine nucleotide

<130> 11183

10

<150> JP99/29783

<151> 1999-02-08

<160> 4

15

<210> 1

<211> 47

<212> DNA

<213> Artificial Sequence

20

<223> Synthetic DNA

<400> 1

ccgcggccta aggaagttac ctgtgtgact caacctgcaa caactcc 47

25

<210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

30

<223> Synthetic DNA

<400> 2

aaaggatcct agaagtttta ctcccactcg atggttcccg 40

35

<210> 3

<211> 47

<212> DNA

<213> Artificial Sequence

5 <223> Synthetic DNA

<400> 3

ccgcggctta aggaagtgac tttgatgaaa tttcccggtta aacgtaa 47

10 <210> 4

<211> 40

<212> DNA

<213> Artificial Sequence

15 <223> Synthetic DNA

<400> 4

aaaggatcca cgataactta acgatcccag taagactctt 40

What is claimed is:

1. A process for producing a purine nucleotide which comprises: culturing in a medium a microorganism having the ability to produce a precursor of the purine nucleotide and carrying an introduced DNA which can induce and express an enzyme capable of synthesizing the purine nucleotide from said precursor; allowing said precursor of the purine nucleotide to accumulate in the culture; inducing and expressing the enzyme capable of synthesizing the purine nucleotide from said precursor; allowing the purine nucleotide formed from said precursor to accumulate in said culture; and then recovering said purine nucleotide therefrom.
2. The process according to claim 1, wherein the precursor of the purine nucleotide is 5'-xanthylic acid, the enzyme capable of synthesizing the purine nucleotide from said precursor is 5'-xanthylic acid aminase, and the purine nucleotide is 5'-guanylic acid.
3. The process according to claim 1, wherein the precursor of the purine nucleotide is guanosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-guanylic acid.
4. The process according to claim 1, wherein the precursor of the purine nucleotide is inosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase, and the purine nucleotide is 5'-inosinic acid.
5. The process according to claim 1, wherein the microorganism belongs to the genus selected from the group consisting of Corynebacterium, Escherichia and Bacillus.

6. The process according to claim 1, wherein the microorganism is Corynebacterium ammoniagenes.

5 7. The process according to claim 1, which is characterized in that the enzyme capable of synthesizing the purine nucleotide is induced and expressed by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.

10

8. The process according to claim 7, wherein the non-sugar carbon source is acetic acid or acetate.

15 9. A DNA which can induce and express an enzyme capable of synthesizing a purine nucleotide from its precursor.

20 10. The DNA according to claim 9, which can induce and express the enzyme capable of synthesizing the purine nucleotide by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.

25 11. The DNA according to claim 10, wherein the non-sugar carbon source is acetic acid or acetate.

12. The DNA according to claim 9 or 10, which is pLAC857 or pIGK2.

30 13. A microorganism having the ability to produce a precursor of a purine nucleotide and carrying an introduced DNA which can induce and express an enzyme capable of synthesizing the purine nucleotide from said precursor.

35 14. The microorganism according to claim 13, wherein the precursor of the purine nucleotide is 5'-xanthylic acid,

the enzyme capable of synthesizing the purine nucleotide from said precursor is 5'-xanthylic acid aminase, and the purine nucleotide is 5'-guanylic acid.

5 15. The microorganism according to claim 13, wherein
the precursor of the purine nucleotide is guanosine, the
enzyme capable of synthesizing the purine nucleotide from
said precursor is inosine-guanosine kinase or phosphatase,
and the purine nucleotide is 5'-guanylic acid.

10

16. The microorganism according to claim 13, wherein
the precursor of the purine nucleotide is inosine, the enzyme
capable of synthesizing the purine nucleotide from said
precursor is inosine-guanosine kinase or phosphatase, and the
15 purine nucleotide is 5'-inosinic acid.

20

17. The microorganism according to claim 13, which
belongs to the genus selected from the group consisting of
Corynebacterium, Escherichia and Bacillus.

18. The microorganism according to claim 13, which is
Corynebacterium ammoniagenes.

19. The microorganism according to claim 18, which is
25 Corynebacterium ammoniagenes ATCC 6872/pLAC857 (FERM BP-
6639) or Corynebacterium ammoniagenes ATCC 6872/pIGK2 (FERM
BP-6638).

ABSTRACT OF THE DISCLOSURE

The present invention provides a process for producing a purine nucleotide which comprises: culturing in a medium
5 a microorganism having the ability to produce a precursor of the purine nucleotide and carrying an introduced DNA which can induce and express an enzyme capable of synthesizing the purine nucleotide from said precursor; allowing said precursor of the purine nucleotide to accumulate in the
10 culture; inducing and expressing the enzyme capable of synthesizing the purine nucleotide from said precursor; allowing the purine nucleotide formed from said precursor to accumulate in said culture; and then recovering said purine nucleotide therefrom. Microorganisms useful in said process
15 are also provided.

OMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
(Page 1)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled _____

PROCESS FOR PRODUCING PURINE NUCLEOTIDES

the specification of which ☒ is attached hereto ☐ was filed on _____ as United States Application
No. or PCT International Application No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b), of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designates at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

<u>Country</u>	<u>Application No.</u>	<u>Filed (Day/Mo./Yr.)</u>	<u>(Yes/No)</u> <u>Priority Claimed</u>
Japan	29738/99	08/02/99	Yes

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>Application No.</u>	<u>Filed (Day/Mo./Yr.)</u>	<u>Status (Patented, Pending, Abandoned)</u>
------------------------	----------------------------	--

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

FITZPATRICK, CELIA, HARPER & SCINTO
Customer Number: 05514

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
(Page 2)

Full Name of Sole or First Inventor Yutaka Takano

Inventor's signature Yutaka Takano

Date January 11, 2000 Citizen/Subject of Japan

Residence Hofu-shi, Yamaguchi, Japan

Post Office Address c/o Technical Research Laboratories, KYOWA HAKKO KOGYO CO., LTD.
1-1, Kyowa-cho, Hofu-shi, Yamaguchi 747-8522 Japan

Full Name of Second Inventor, if any Masato Ikeda

Inventor's signature Masato Ikeda

Date January 11, 2000 Citizen/Subject of Japan

Residence Hofu-shi, Yamaguchi, Japan

Post Office Address c/o Technical Research Laboratories, KYOWA HAKKO KOGYO CO., LTD.
1-1, Kyowa-cho, Hofu-shi, Yamaguchi 747-8522 Japan

Full Name of Third Joint Inventor, if any Tatsuro Fujio

Third Inventor's signature Tatsuro Fujio

Date January 14, 2000 Citizen/Subject of Japan

Residence Sagamihara-shi, Kanagawa, Japan

Post Office Address c/o Head Office, KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohtemachi 1-chome, Chiyoda-ku, Tokyo 100-8185 Japan

Full Name of Fourth Joint Inventor, if any _____

Fourth Inventor's signature _____

Date _____ Citizen/Subject of _____

Residence _____

Post Office Address _____

Full Name of Fifth Joint Inventor, if any _____

Fifth Inventor's signature _____

Date _____ Citizen/Subject of _____

Residence _____

Post Office Address _____

Full Name of Sixth Joint Inventor, if any _____

Sixth Inventor's signature _____

Date _____ Citizen/Subject of _____

Residence _____

Post Office Address _____

Full Name of Seventh Joint Inventor, if any _____

Seventh Inventor's signature _____

Date _____ Citizen/Subject of _____

Residence _____

Post Office Address _____

Fig. 1




Fig. 2





Fig. 3



Application Data Sheet

Application Information

Application Type::	Utility
Subject Matter::	Utility
CD_ROM or CD-R?::	None
Sequence submission?::	Paper
Computer Readable Form (CRF)?::	No
Title::	PROCESS FOR PRODUCING PURINE NUCLEOTIDES
Attorney Docket Number::	02139.000017.1
Suggested Drawing Figure::	1
Total Drawing Sheets::	3
Small Entity?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Primary Citizenship Country::	Japan
Status::	Full Capacity
Given Name::	Yutaka
Family Name::	Takano
City of Residence::	Hofu-shi
State or Province of Residence::	Yamaguchi
Country of Residence::	Japan
Street of mailing address::	c/o Tech. Res. Lab., KYOWA HAKKO KOGYO 1-1, Kyowa-cho
City of mailing address::	Hofu-shi
State or Province of mailing address::	Yamaguchi
Country of mailing address::	Japan

Postal or Zip Code of mailing address:: 747-8522

Primary Citizenship Country:: Japan

Status:: Full Capacity

Given Name:: Masato

Family Name:: Ikeda

City of Residence:: Hofu-shi

State or Province of Residence:: Yamaguchi

Country of Residence:: Japan

Street of mailing address:: c/o Tech. Res. Lab., KYOWA HAKKO KOGYO
1-1, Kyowa-cho

City of mailing address:: Hofu-shi

State or Province of mailing address:: Yamaguchi

Country of mailing address:: Japan

Postal or Zip Code of mailing address:: 747-8522

Primary Citizenship Country:: Japan

Status:: Full Capacity

Given Name:: Tatsuro

Family Name:: Fujio

City of Residence:: Sagamihara-shi

State or Province of Residence:: Kanagawa

Country of Residence:: Japan

Street of mailing address:: c/o Head Office, KYOWA HAKKO KOGYO CO.
6-1, Ohtemachi 1-chome

City of mailing address:: Chiyoda-ku

State or Province of mailing address:: Tokyo

Country of mailing address:: Japan

Postal or Zip Code of mailing address:: 100-8185

Correspondence Information

Correspondence Customer Number:: 5514

Representative Information

Representative Customer Number::	05514
----------------------------------	-------

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	Continuation of	09/496,041	02/02/2000

Foreign Priority Information

Country::	Application Number::	Filing Date::	Priority Claimed::
Japan	29738/99	02/08/1999	Yes

Assignee Information

Assignee name:: KYOWA HAKKO KOGYO CO., LTD.
Street of mailing address:: 6-1, Ohtemachi 1-chome
City of mailing Address:: Chiyoda-ku
State or Province of mailing address:: Tokyo
Country of mailing address:: Japan
Postal or Zip Code of mailing address:: 100-8185

02139.000017.1

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
	:	Prior Examiner: Kathleen M. Kerr
YUTAKA TAKANO, ET AL.)	
	:	Prior Group Art Unit: 1652
Application No.: (Continuation of Appl.)	
No. 09/496,041 filed February 2, 2000)	:	
)	
Filed: Concurrently herewith	:	
)	
For: PROCESS FOR PRODUCING	:	
PURINE NUCLEOTIDES)	April 24, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the above-identified application
as follows:

a.) Introductory Comments

The present amendment has been prepared in accordance with the Revised Format established by the U.S. Patent and Trademark Office, as permitted in the Pre-OG Notice entitled "Amendments in a Revised Format Now Permitted", a copy of which is attached.

b.) Amendments to the Specification^{1/}

Please insert the following new paragraph on page 1 after line 2, before line 3.

This application is a continuation of application No. 09/496,041 filed February 2, 2000.

Please amend the paragraph starting at page 6, line 30 to page 7, line 5 to read as follows.

- (1) A process for producing a purine nucleotide which comprises: culturing in a medium a microorganism having the ability to produce a precursor of the purine nucleotide and carrying an introduced DNA which can ~~induce and~~ express an enzyme capable of synthesizing the purine nucleotide from said precursor upon induction; allowing said precursor of the purine nucleotide to accumulate in the culture; inducing ~~and expressing~~ the expression of the enzyme capable of synthesizing the purine nucleotide from said precursor and expressing said enzyme; allowing the purine nucleotide formed from said precursor to accumulate in said culture; and then recovering said purine nucleotide therefrom.

Please amend the paragraph at page 7, lines 27-33 to read as follows.

- (7) The process according to the above (1), which is characterized in that the expression of the enzyme capable of synthesizing the purine nucleotide is induced

^{1/}

Where appropriate, e.g., where the original text is underlined, the material deleted and added herein is shown in bold.

~~and expressed~~ by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.

Please amend the paragraphs starting at page 7, line 36 and ending at page 8, line 7 to read as follows.

- (9) A DNA which can ~~induce and~~ express an enzyme capable of synthesizing a purine nucleotide from its precursor upon induction.
- (10) The DNA according to the above (9), which can ~~induce and~~ express the enzyme capable of synthesizing the purine nucleotide upon induction by the change of condition selected from the group consisting of rise in temperature, rise in pH and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.

Please amend the paragraph at page 8, lines 12- 15 to read as follows.

- (13) A microorganism having the ability to produce a precursor of a purine nucleotide and carrying an introduced DNA which can ~~induce and~~ express an enzyme capable of synthesizing the purine nucleotide from said precursor said precursor.

Please amend the paragraph at page 13, lines 5-12 to read as follows.

The thus obtained gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor is inserted into an appropriate inducible-expression vector so that the gene is under the control of the transcription and translation signal capable of regulating its ~~induction and~~ expression, whereby a recombinant plasmid which can regulate the expression of said gene can be obtained.

Please amend the paragraphs at page 15, lines 6-31 to read as follows. The changes are in bold.

On the other hand, when the transcription-translation signal related to the regulation of gene expression in the inducible-expression vectors does not function in a microorganism to be used, or when it functions but the above three requirements are not sufficiently fulfilled, it is necessary to improve said transcription-translation signal region by mutation techniques or recombinant DNA techniques so that the above three requirements can be fulfilled, or to develop a new system of **induction and inducible** expression applicable to said microorganism. In the former case, the improvement can be carried out, for example, by site-directed mutagenesis referring to a transcription-translation signal sequence known for the microorganism to be used. In the latter case, the new system can be developed and constructed according to the method of developing the above general inducible-expression systems constructed for Escherichia coli, etc.

Preferred examples of the microorganisms carrying the inducible-expression system include Corynebacterium ammoniagenes strains, etc., which were respectively developed using, as the **gene-inducing and expressing inducible-gene-expression** system, a temperature-inducible plasmid vector which is prepared by ligating the P_L promoter/cl857 gene carried by pPAC31 which is a vector induced at a high temperature in Corynebacterium, and pCEX2 capable of regulating the expression by addition of inexpensive acetic acid.

Please amend the paragraphs at page 16, lines 4-32 to read as follows. The changes are in bold.

The inducible-express plasmid containing the gene encoding the enzyme capable of synthesizing a purine nucleotide from its precursor can be introduced into a microorganism which produces the precursor of the purine nucleotide by using the protoplast method, ~~the electric pulse method~~ **electroporation**, the calcium chloride method, and conventional methods described in Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter abbreviated as Molecular Cloning, Second Edition), etc.

For example, when a bacterium belonging to the genus Corynebacterium is used as the host microorganism, the protoplast method (Japanese Published Unexamined Patent Application No. 183799/82) and ~~the electric pulse method~~ **electroporation** (Japanese Published Unexamined Patent Application No. 207791/90) are particularly effective. When Escherichia coli is used as the host microorganism, the calcium chloride method [J. Mol. Biol., 53, 159 (1970)], etc. can also be employed.

The **expression of the** enzyme capable of synthesizing a purine nucleotide from its precursor can be induced ~~and expressed~~ by culturing the thus obtained transformant of the present invention carrying the introduced gene encoding the enzyme capable of synthesizing the purine nucleotide from its precursor in an ordinary medium containing carbon sources, nitrogen sources and inorganic substances, and additionally, trace organic nutrients, as may be required, to form and accumulate the precursor of the purine nucleotide, and then subjecting the resulting culture to the induction treatment such as heating or addition of acetic acid.

Please amend the paragraph at page 20, lines 4-9 to read as follows. The changes are in bold.

The plasmid was cleaved with various restriction enzymes and analyzed, whereby it was confirmed that plasmid pLS857 comprising the XMP aminase gene **which was under the control of the P_L promoter**, the cl1857 gene, the ampicillin resistance gene and the replication origin of the plasmid autonomously replicable in Escherichia coli **in the region under the control of the P_E promoter** was obtained.

Please amend the paragraph at page 20, lines 28-35 to read as follows. The changes are in bold.

Corynebacterium ammoniagenese ATCC 6872 was transformed using 1 µg of the DNA obtained by the ligation treatment by means of **the electric pulse method electroporation** [Appl. Microbiol. Biotechnol., 30, 283 (1989)] and then spread on A agar medium [0.5% glucose, 1% peptone, 0.5% meat extract, 0.5% yeast extract, 0.25% sodium chloride, 1.5% agar, 10 mg/1 adenine and 10 mg/1 guanine (pH 7.2)] containing 100 µg/ml spectinomycin.

Please amend the paragraph at page 21, lines 19-23 to read as follows. The changes are in bold.

An XMP-producing strain of Corynebacterium ammoniagenes, FERM BP-1261 (Japanese Patent No. 2618383:adenine-leaky requiring and guanine-requiring), was transformed using said plasmid by the above **electric pulse method electroporation**.

Please amend the paragraph at page 24, lines 8-12 to read as follows.

To induce ~~and express~~ the expression of the XMP aminase gene, the culture broth was heated to 40°C, and kept at the same temperature with stirring (600 rpm) and aeration (1 l/min) for 6 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

Please amend the paragraph at page 26, lines 23-26 to read as follows. The changes are in bold.

Corynebacterium ammoniagenes ATCC 6872 was transformed using said ligated DNA (1 µg) by ~~the electric pulse method~~ **electroporation**, and then spread on A agar medium containing 100 µg/ml spectinomycin.

Please amend the paragraph at page 27, lines 4-7 to read as follows. The changes are in bold.

An XMP-producing strain of Corynebacterium ammoniagenes, FERM BP-1261 (adenine-leaky requiring and guanine-requiring), was transformed using said plasmid by ~~the electric pulse method~~ **electroporation**.

Please amend the paragraph at page 28, lines 13-18 to read as follows.

After the fermentation was completed, in order to induce ~~and express~~ the express of the XMP aminase gene, ammonium acetate was added to the fermentation broth to a final concentration of 2%, followed by culturing with stirring (600 rpm) and aeration (1 l/min) for 10 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

Please amend the paragraph at page 31, lines 6-9 to read as follows. The changes are in bold.

Corynebacterium ammoniagenes ATCC 6872 was transformed using this plasmic (1 μ g) by ~~the electric pulse method~~ **electroporation** method and then spread on A agar medium containing 100 μ g /ml spectinomycin.

Please amend the paragraph at page 31, lines 27-30 to read as follows. The changes are in bold.

An inosine-producing strain of Corynebacterium ammoniagenes, FERM BP-2217 (Japanese Patent No. 2578496:adenine-leaky requiring and guanine-requiring), was transformed using said plasmic by ~~the electric pulse method~~ **electroporation**.

Please amend the paragraph at page 34, lines 16-21 to read as follows.

After the culturing was completed, in order to induce ~~and express~~ **the expression of** the inosine-guanosine kinase gene, ammonium acetate was added to the obtained culture to a final concentration of 2%, following by culturing with stirring (600 rpm) and aeration (1 l/min) for 10 hours, during which the pH was kept at 7.2 with 5.5 mol/l aqueous ammonia.

IN THE ABSTRACT:

Please rewrite the Abstract at page 40 to read as follows:

ABSTRACT OF THE DISCLOSURE

Purine nucleotides are produced by culturing a microorganism having the ability to produce a precursor of the purine nucleotide and carrying an introduced DNA which can express an enzyme capable of synthesizing the purine nucleotide from the precursor upon induction; allowing the purine nucleotide precursor to accumulate in the culture; inducing the expression of the enzyme; allowing the purine nucleotide formed to accumulate in the culture; and recovering the purine nucleotide. Suitable microorganisms include *Corynebacterium ammoniagenes* which are induced to express GMP synthetase/XMP aminase and inosine-guanosine kinase for use in producing IMP and GMP, especially from the nucleotide precursor XMP.

c.) Amendments to the Claims

1. (Currently Amended) A process for producing a purine nucleotide which comprises:-

culturing in a medium a recombinant microorganism obtained by transforming a host cell having the ability to produce a precursor of the purine nucleotide ~~and carrying an introduced DNA which can induce and~~ selected from the group consisting of XMP, guanosine, inosine and adenosine with DNA which can express an enzyme capable of synthesizing the purine nucleotide from said precursor; ~~allowing upon induction, to accumulate~~ said precursor of the purine nucleotide ~~to accumulate~~ in the culture;

inducing ~~and expressing the expression of~~ the enzyme capable of synthesizing the purine nucleotide from said precursor; ~~allowing to form~~ the purine nucleotide ~~formed from said the accumulated~~ precursor ~~to accumulate~~ in said culture; and then

recovering ~~said the formed~~ purine nucleotide therefrom.

2. (Original) The process according to claim 1, wherein the precursor of the purine nucleotide is 5'-xanthylic acid, the enzyme capable of synthesizing the purine nucleotide from said precursor is 5'-xanthylic acid aminase, and the purine nucleotide is 5'-guanylic acid.

3. (Currently Amended) The process according to claim 1, wherein the precursor of the purine nucleotide is guanosine, the enzyme capable of synthesizing the

purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase derived from *Morganella morganii*, and the purine nucleotide is 5'-guanylic acid.

4. (Currently Amended) The process according to claim 1, wherein the precursor of the purine nucleotide is inosine, the enzyme capable of synthesizing the purine nucleotide from said precursor is inosine-guanosine kinase or phosphatase derived from *Morganella morganii*, and the purine nucleotide is 5'-inosinic acid.

5. (Original) The process according to claim 1, wherein the microorganism belongs to the genus selected from the group consisting of *Corynebacterium*, *Escherichia* and *Bacillus*.

6. (Original) The process according to claim 1, wherein the microorganism is *Corynebacterium ammoniagenes*.

7. (Original) The process according to claim 1, which is characterized in that the enzyme capable of synthesizing the purine nucleotide is induced and expressed by the change of a condition selected from the group consisting of rise in temperature, rise in pH, and rise in osmotic pressure, or by the change of the carbon source from sugars to non-sugars.

8. (Currently Amended) The process according to claim 7 20, wherein the non-sugar carbon source is acetic acid or acetate.

Claims 9-19 (Cancelled)

20. (New) The process according to claim 7, wherein expression of the enzyme is induced by change of carbon source from a sugar carbon source to a non-sugar carbon source.


d.) Remarks

The claims and specification have been amended to make the changes of record in the parent application. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY_MAIN 342151v1

02139.000017.1

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
	:	Prior Examiner: Kathleen M. Kerr
YUTAKA TAKANO, ET AL.)	
	:	Prior Group Art Unit: 1652
Application No.: (Continuation of Appl)	
No. 09/496,041 filed February 2, 2000)	:	
)	
Filed: Concurrently herewith	:	
)	
For: PROCESS FOR PRODUCING	:	
PURINE NUCLEOTIDES)	April 24, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. The documents are being cited because they were cited previously in Applicants' parent application.

In conformity with M.P.E.P. § 609(2)¶ 2, copies of the references are not enclosed. The Examiner is respectfully invited to review the parent application for such documents.

It is respectfully requested that the above information be considered by the Examiner.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. 02139.000017.1		APPLICATION NO. Continuation of 09/496,041	
				APPLICANT Yutaka Takano, et al.			
				FILING DATE Concurrently herewith		PRIOR GROUP 1652	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,439,822	8/1995	Katsumata, et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
		91/08286	6/13/91	PCT			
		0458971	1/3/96	EP			
		96/30501	10/3/96	PCT			
		0816491	1/7/98	EP			
		9-37785	10/2/97	Japan			
		0832970	4/1/98	EP			
		10-201481	8/4/98	Japan			
		0857788		EP			
		39-2985	8/23/89	Japan			Abstract
		42-1186	1/20/42	Japan			Abstract
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Food Technology, 18, 287 (March 1964), pages 29-35.					
		Bulletin of the Chemical Society of Japan, Vol 42 (1969), pages 3505-3508.					
		Biotechnology and Bioengineering, Vol. IX (1967), pages 329-342.					
		J. Org. Chem., Vol. 32 (1967), pages 1825-1828.					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. 02139.000017.1		APPLICATION NO. Continuation of 09/496,041	
				APPLICANT Yutaka Takano, et al.			
				FILING DATE Concurrently herewith		PRIOR GROUP 1652	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
		49-44350	11/27/74	Japan			Abstract
		53-56390	5/22/78	Japan			Abstract
		56-82098	7/4/81	Japan			Abstract
		63-230094	9/26/88	Japan			
		0282989	10/6/93	EP			
		63-233798	9/29/88	Japan			
		0263716	4/13/98	EP			
		0 236 716	9/16/87	EP			
		0 251 489	1/7/88	EP			
		0 185 092	6/25/86	EP			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Biosci. Biotech, Biochem., Vol. 61 (1997), pages 840-845.
	Shoichi Takao, et al., (ed.), Oyo Biseibutsugaku (Applied Microbiology), Buneido Shuppan (1996), pages 312-331.
	Agricultural and Biological Chemistry, Vol. 42 (1978), pages 399-405.
	Agricultural and Biological Chemistry, Vol. 43 (1979), pages 1739-1744.
	Agricultural and Biological Chemistry, Vol. 46 (1982), pages 2347-2352.
	Agricultural and Biological Chemistry, Vol. 46 (1982), pages 2257-2263.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. 02139.000017.1		APPLICATION NO. Continuation of 09/496,041	
				APPLICANT Yutaka Takano, et al.			
				FILING DATE Concurrently herewith		PRIOR GROUP 1652	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Journal of Bacteriology, Vol. 177, No. 17 (Sept. 1995), pages 4921-4926.
		Applied Microbiol. and Biotechnol., Vol. 48, No. 6 (December 1997), pages 693-698.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3



UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

02139.000017.1

First Named Inventor or Application Identifier

Yutaka Takano

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.

3. ☒ Specification Total Pages

4. ☒ Drawing(s) (35 USC 113) Total Sheets

5. ☒ Oath or Declaration Total Pages

a. ☐ Newly executed (original or copy)

b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

i. ☐ **DELETION OF INVENTOR(S)**
Signed Statement attached deleting
inventor(s) named in the prior application, see
37 CFR 1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer
Program (Appendix)

8. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Form (CRF)

b. Specification Sequence Listing on:

i. ☐ CD-ROM or CD-R (2 copies); or

ii. ☒ paper

c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))

10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)

11. ☐ English Translation Document (if applicable)

12. ☒ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations

13. ☒ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Other: _____

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 09/496,041

Prior application information:

Examiner Kathleen M. Kerr

Group/Art Unit: 1652

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME

Address

City

State

Zip Code

Country

Telephone

Fax



CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	9-20 =	0	X \$ 18.00 =	\$0.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1-3 =	0	X \$ 84.00 =	\$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			\$280.00 =	\$0.00
				BASIC FEE (37 CFR 1.16(a))	\$750.00
			Total of above Calculations =		\$750.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				
	TOTAL =				\$750.00

19. Small entity status


- a. ☐ A small entity statement is enclosed
- b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.

20. ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.

21. ☐ A check in the amount of \$ _____ to cover the recordal fee is enclosed.

22. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 06-1205:

- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	Lawrence S. Perry Registration No. 31,865
SIGNATURE	
DATE	April 24, 2003

02139.000017.1

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
	:	Prior Examiner: Kathleen M. Kerr
YUTAKA TAKANO, ET AL.)	
	:	Prior Group Art Unit: 1652
Application No.: (Continuation of Appl.)	
No. 09/496,041 filed February 2, 2000)	:	
)	
Filed: Concurrently herewith	:	
)	
For: PROCESS FOR PRODUCING	:	
PURINE NUCLEOTIDES)	April 24, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231


STATEMENT CONCERNING COMPUTER READABLE FORM

Sir:

Under the provision of 37 C.F.R. § 1.821(e), the Sequence Listing herein is identical to that in the parent application No.09/496,041. Applicant hereby requests that the compliant Computer Readable Form of record therein be utilized in this application as well.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY_MAIN 342949v1

Sequence Listing

<110> Yutaka TAKANO
Masato IKEDA
Tatsuro FUJIO

<120> Process for producing purine nucleotides

<130> 1183

<150> JP99/29783

<151> 1999-02-08

<160> 4

<210> 1

<211> 47

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

<400> 1

ccgcggctta aggaagttac ctgtgtgact caacctgcaa caactcc 47

<210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

<400> 2

aaaggatcct agaagtttta ctcccactcg atgggtcccg 40

<210> 3

<211> 47

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

<400> 3

ccgcggctta aggaagtgcac ttgatgaaa tttcccggta aacgtaa 47

<210> 4

<211> 40

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

<400> 4

aaaggatcca cgataactta acgatcccag taagactctt 40